Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Return on Invested Capital (2016 - 2025)

Historic Return on Invested Capital for Myriad Genetics (MYGN) over the last 15 years, with Q3 2025 value amounting to 0.84%.

  • Myriad Genetics' Return on Invested Capital fell 6900.0% to 0.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.84%, marking a year-over-year decrease of 6900.0%. This contributed to the annual value of 0.16% for FY2024, which is 1400.0% up from last year.
  • Myriad Genetics' Return on Invested Capital amounted to 0.84% in Q3 2025, which was down 6900.0% from 0.65% recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Return on Invested Capital ranged from a high of 0.04% in Q1 2022 and a low of 0.84% during Q3 2025
  • Its 5-year average for Return on Invested Capital is 0.23%, with a median of 0.16% in 2021.
  • As far as peak fluctuations go, Myriad Genetics' Return on Invested Capital surged by 2100bps in 2024, and later crashed by -6900bps in 2025.
  • Quarter analysis of 5 years shows Myriad Genetics' Return on Invested Capital stood at 0.09% in 2021, then crashed by -33bps to 0.12% in 2022, then crashed by -169bps to 0.33% in 2023, then skyrocketed by 50bps to 0.17% in 2024, then plummeted by -401bps to 0.84% in 2025.
  • Its last three reported values are 0.84% in Q3 2025, 0.65% for Q2 2025, and 0.13% during Q1 2025.